oral CXCR3 antagonist

efficacy in mice model of lung inflammation

from HTS and opt

J. Med. Chem.

Idorsia Pharmaceuticals Ltd., Allschwil, CH

ACT-660602 chemical structure oral CXCR3 antagonist - Idorsia Pharmaceuticals Ltd., Allschwil, CH

Context. ACT-660602 (Idorsia Pharmaceuticals) is an oral chemokine receptor CXCR3 antagonist being developed for autoimmune diseases. Chemokines and their receptors make up the signaling system that is responsible for…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: